Why is Medicamen Biotec falling/rising?

As of 02-Sep, Medicamen Biotech Ltd's stock price is currently at Rs 349.80, reflecting an increase of Rs 4.75 or 1.38%. The stock has shown a positive performance today, outperforming its sector by 1.45% and has been gaining for the last two days, with a total return of 1.77% during this period. However, it is still close to its 52-week low, just 2.23% away from Rs 342. The stock's performance over the past month indicates a decline of 9.04%, and it has underperformed significantly over the year with a return of -13.20%. Despite a low debt-to-equity ratio and a fair valuation, the company has faced challenges such as poor long-term growth, with operating profit declining at an annual rate of -12.66% over the last five years.
In the broader market context, the stock's short-term return of +0.24% over the past week stands in contrast to the Sensex, which has decreased by 0.78%. This indicates that while Medicamen Biotech is experiencing a slight recovery, it has consistently underperformed against the benchmark over the longer term, particularly in the last three years. The company's recent profit increase of 28.3% has not translated into stock performance, as evidenced by its negative returns and low ROCE. The overall market sentiment appears to be cautious, especially given the stock's historical underperformance and declining investor participation, which may contribute to the mixed signals surrounding its recent price movements.